<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1324">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089645</url>
  </required_header>
  <id_info>
    <org_study_id>D6840C00001</org_study_id>
    <nct_id>NCT03089645</nct_id>
  </id_info>
  <brief_title>MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and
      antitumor activity in adult subjects with selected advanced solid tumor malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global Phase 1, first-time-in-human, multicenter, open-label, dose-escalation and
      dose-expansion study of MEDI5083 alone and in combination with durvalumab.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 7, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs) as a measure of safety</measure>
    <time_frame>From the time of consent through 120 days after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>From the time of consent through 120 days after last treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Dose Limiting Toxicities (DLTs) as a measure of safety</measure>
    <time_frame>From the time of first dose through 28 days thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The Maximum Tolerated Dose (MTD) or Highest Protocol-Defined Dose</measure>
    <time_frame>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Discontinuation Rate</measure>
    <time_frame>From the time of first dose through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum MEDI5083 concentration levels</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Pharmacokinetics (PK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in peripheral blood CD19+ B cells</measure>
    <time_frame>From the time of first dose through 57 days after first treatment</time_frame>
    <description>Pharmacodynamics (PD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) responses to MEDI5083</measure>
    <time_frame>From the time of first dose through 2 years after last treatment</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) at 6 months (PFS-6)</measure>
    <time_frame>From the time of first dose until 6 months after the last subject is dosed</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From the time of consent through end of study (2 years after last subject enrolled or earlier at sponsor discretion)</time_frame>
    <description>Clinical Activity Endpoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Durvalumab concentration levels</measure>
    <time_frame>From the time of first dose through 29 days after first treatment</time_frame>
    <description>Pharmacokinetics (PK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) responses to Durvalumab</measure>
    <time_frame>From the time of first dose through 2 years after last treatment</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Selected Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI5083 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI5083 with durvalumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI5083 monotherapy</intervention_name>
    <description>Dose-escalation MEDI5083 monotherapy</description>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEID5083 with durvalumab</intervention_name>
    <description>MEDI5083 dose-escalation with durvalumab therapy</description>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years at the time of screening or age of consent according to local law

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          3. Histologically or cytologically confirmed metastatic or recurrent tumor types

          4. Subjects who have received prior immunotherapy may be eligible

          5. Subjects must have at least one measurable lesion

          6. Consent to provide archival tumor tissue and pre/on-treatment biopsies

          7. Adequate organ and marrow function

          8. Consent to use one highly effective method of contraception

        Exclusion Criteria:

          1. Receipt of any systemic anticancer therapy within 28 days prior to the first dose of
             MEDI5083

          2. Concurrent enrollment in another clinical study

          3. Active/prior autoimmune of inflammatory disorders

          4. History of immunodeficiency, solid organ transplant, or tuberculosis

          5. Known allergy/hypersensitivity to drug or components

          6. Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or
             cord compression

          7. Current or prior use of immunosuppressive medication within 14 days prior to the
             first dose of MEDI5083
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MedImmune LLC</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>AstraZeneca Cancer Study Locator Service</last_name>
    <phone>1-877-400-4656</phone>
    <email>AstraZeneca@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>January 19, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
